All companies
Visit website
Phoenix PharmaLabs Inc
OperatingHealthcare · Founded 2002
Addressing the opioid crisis by developing potent, safe, non-addictive painkillers.
Post-money valuation ⓘ
$26.8M
As of Feb 2021 · from Phoenix PharmaLabs Inc Stock 2 · pre-money + amount raised, not a traded price
Total raised
$1,065,500
Across 2 rounds since 2018
Latest share price
$1.00
Phoenix PharmaLabs Inc Stock 2 offering price
Financials
FY2016–FY2023 · from SEC filings · hover any figure for its source$0
−$1.3M
2016
$0
−$1.1M
2017
$67K
−$940K
2018
$1.3M
−$478K
2019
$167K
−$1.0M
2022
$2.1M
−$884K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2016
FY2017
FY2018
FY2019
FY2022
FY2023
Income statement
Revenue
$0
$0
$66,654
$1,285,068
$167,209
$2,065,804
Cost of goods sold
$0
$0
$0
$0
$0
$0
Gross margin
—
—
100%
100%
100%
100%
Net income
-$1,270,142
-$1,094,446
-$939,817
-$477,945
-$1,015,172
-$884,105
Taxes paid
$0
$0
$100
$0
$0
$0
Balance sheet
Cash
$29,732
$151,025
$37,344
$761,206
$307,170
$796,285
Accounts receivable
$0
$0
$0
$0
$0
$0
Total assets
$29,757
$151,050
$37,344
$761,206
$307,170
$796,285
Short-term debt
$1,417,549
$1,871,549
$1,964,449
$2,058,665
$0
$0
Long-term debt
$0
$0
$0
$0
$3,358,257
$5,328,028
Total liabilities
$1,417,549
$1,871,549
$1,964,449
$2,058,665
$3,358,257
$5,328,028
Other
Headcount
—
5
—
5
—
4
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$26.8M
post-money
Phoenix PharmaLabs Inc Stock 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised — / $1.1MPost-money $26.8M
Raised $1.1M / $1.1M
Reg CF annual-report compliance
Possibly delinquent
Filed 2 of 8 annual reports (FY2018–FY2025)
Missing: 2018, 2020, 2021, 2022, 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 15 filings on EDGARSource: ManualCIK 0001755778Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.